Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001194109 | SCV001363391 | benign | not specified | 2019-08-13 | criteria provided, single submitter | clinical testing | Variant summary: ACTC1 c.809-28_809-13delTGTGTGTGTGTGTGTG alters a nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. 5/5 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.14 in 24922 control chromosomes in the gnomAD database, including 256 homozygotes. The observed variant frequency is approximately 5553-folds over the estimated maximal expected allele frequency for a pathogenic variant in ACTC1 causing Cardiomyopathy phenotype (2.5e-05), strongly suggesting that the variant is benign. To our knowledge, no occurrence of c.809-28_809-13del16 in individuals affected with Cardiomyopathy and no experimental evidence demonstrating its impact on protein function have been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as benign. |
Gene |
RCV001673034 | SCV001891190 | benign | not provided | 2019-08-11 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002069248 | SCV002351273 | likely benign | Hypertrophic cardiomyopathy 11; Dilated cardiomyopathy 1R; Atrial septal defect 5 | 2024-02-01 | criteria provided, single submitter | clinical testing |